Most people in biotech are trying to discover something. He is trying to finish it.
In April 2024 a small cancer-immunotherapy company in the Bay Area handed its top job to someone who had spent a quarter century being handed exactly that kind of job. Actym Therapeutics is building a strange and promising idea - engineered bacteria that slip into the immune-suppressed core of a tumor and switch on gene therapy from the inside. The science is somebody else's. The question of whether the science ever reaches a patient is Tom Smart's.
That distinction is the whole career. Drug discovery gets the magazine covers; Smart works the part nobody photographs - the financings, the licensing tables, the board votes, the acquisition that lets a clinical-stage asset live another year. He has done it at companies you have heard of and companies you have not, across antibodies, small molecules, peptides, RNA, DNA, CAR-T and cell therapies. The modality changes. The job does not.
His clearest fingerprint is on a checkpoint inhibitor. During his run as chief executive and board chair of AnaptysBio, the company advanced a PD-1 antibody that the wider industry would come to know, after a long relay of partnerships, as dostarlimab - GSK's Jemperli, eventually approved on both sides of the Atlantic. Smart did not invent the antibody. He helped build the company and the deals that carried it out of the lab, which in biotech is its own kind of authorship.
Then he did the thing serial operators do: he started his own. Gravitas Therapeutics was built around a single clinical-stage antifungal, GR-2397. There was no sprawling pipeline, no platform story, just one asset and a thesis. In October 2023 he sold it to Basilea Pharmaceutica, the publicly traded Swiss specialty-pharma house, and moved on. Six months later he was running Actym.
Industry records also list him as chief executive and a board member at Seneca Therapeutics, the Pennsylvania company developing an oncolytic Seneca Valley virus that hunts tumors carrying the TEM8 receptor. Oncolytic viruses, bacteria-delivered gene therapy, checkpoint antibodies - the through-line is not a technology. It is a temperament for the awkward stretch between a good result and a real medicine.
Actym represents an exceptional opportunity to achieve a new level of therapeutic impact across multiple tumor types.Tom Smart, on taking the chief executive role - 2024
He has carried companies across the line that breaks most of them - from quiet private financings into the glare and discipline of public markets.
Bench science to first-in-human is where money and patience run out. Moving an asset across that gap is the work he keeps being hired to do.
Private rounds, initial public offerings - the unromantic plumbing that keeps a pipeline alive long enough to matter.
Corporate partnerships and acquisitions, including the Gravitas-to-Basilea sale, are his signature - finding the buyer or partner a molecule needs.
Antibodies, small molecules, peptides, RNA, DNA, CAR-T, cell therapies, oncolytic viruses. He bets on outcomes, not on a favorite technology.
CEO, Chief Business Officer, SVP, board chair, board member. He has sat on every side of the table a biotech has to offer.
Most executives specialize in one corner of the periodic table of medicine. Smart's public record spans an uncommon range of therapeutic modalities. The bars below are a qualitative map of where his career has reached - not financial data, just the breadth of the terrain.
* Genetics Institute and Searle, two of his early employers, were both eventually absorbed into Pfizer. Breadth bars are illustrative of career scope, not quantitative metrics.
Companies in his history were later swallowed by Pfizer - Genetics Institute, Searle and the gene-therapy lineage he worked inside. He has been a quiet part of the consolidation of an entire industry.
A Cornell science degree welded to a Chicago Booth MBA - the classic lab-to-boardroom hybrid that explains why he is fluent in both the assay and the term sheet.
He built an entire company, Gravitas, around a single asset. No platform, no portfolio hedge - just GR-2397 and the conviction to find it a home at Basilea.
His modality list reads like a syllabus: antibodies, small molecules, peptides, RNA, DNA, CAR-T, cell therapies. Few executives can credibly claim all of them.
At Seneca Therapeutics the target is a receptor most people have never heard of - TEM8 / ANTXR1 - hunted by a virus that is harmless to humans but lethal to certain tumors.
Six months after closing the Gravitas sale he was already running another company. Operators like Smart do not retire between rounds - they reload.
Actym's bet is that the tumor microenvironment - the hostile, immune-suppressed zone where most therapies stall - can be turned into a delivery route rather than a dead end. Engineered bacteria home to that zone and release gene-encoded immune payloads where they are needed most. It is early, it is strange, and it is exactly the kind of thing that needs an operator who has shepherded strange ideas before.
If the pattern holds, the next few years are about the same things they always are for Tom Smart: the financing that keeps the lights on, the partnership that adds firepower, the clinical step that turns a hypothesis into evidence. He has never been the scientist with the breakthrough. He has reliably been the one who makes sure the breakthrough doesn't die in a freezer.